Development of a tube enzyme immunoassay for 'on-site' screening of urine samples in the presence of β-agonists

• Published in: Analyst (London) Vol. 121; no. 8; pp. 1111 - 1114
• Main Authors: HAASNOOT, W, STREPPEL, L, CAZEMIER, G, SALDEN, M, STOUTEN, P, ESSERS, M, VAN WICHEN, P
• Format: Journal Article
• Language: English
• Published: Cambridge Royal Society of Chemistry 01.08.1996
• Subjects: Adrenergic beta-Agonists - urine; Animal productions; Animals; Biological and medical sciences; Cattle; Fundamental and applied biological sciences. Psychology; Immunoenzyme Techniques; Methods; Sensitivity and Specificity; Terrestrial animal productions; Vertebrates; Urine; Biological fluid; Farming animal; Bovine; Veterinary medicine; Enzyme immunoassay; Vertebrata; Mammalia; Investigation method; Detection limit; Artiodactyla; Anabolic agent; Ungulata; Quantitative analysis
• ISSN: 0003-2654; 1364-5528
• DOI: 10.1039/AN9962101111

An on-site screening test for the detection of beta-agonistic drugs in urine was developed. The test is based on the principle of an enzyme immunoassay in polystyrene tubes. Results can be obtained by visual interpretation or by measurement with a differential photometer. The total time required to perform the test for a set of samples (five samples+one cut-off standard) is about 20 min (visual interpretation) with an additional 2 min for an instrumental interpretation. Owing to its speed and simplicity, the test can be performed in slaughter- and farmhouses. In the tube test, a mixture of antibodies raised against clenbuterol and salbutamol is used, which makes this test sensitive towards a range of beta-agonists (multi-test). In this study, the test was applied to the screening of 269 bovine urine samples. Bovine urine samples with a level of 3 ng ml-1 of clenbuterol and higher were found positive with this on-site test. Owing to fewer matrix effects, a lower level (1 ng ml-1) could be detected in calf urine. The detection of positive samples at the place of sampling can result in more effective control of the illegal use of beta-agonists.